Kamada (KMDA) Non-Current Assets (2012 - 2026)
Kamada (KMDA) posted quarterly Non-Current Assets of $183.8 million for Q1 2026, down 1.51% year-on-year from $186.6 million in Q1 2025, and down 1.0% on a QoQ basis from $185.6 million in Q4 2025.
Kamada (KMDA) Non-Current Assets (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Non-Current Assets for 13 consecutive years, with $183.8 million the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Assets fell 1.51% year-over-year to $183.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $738.8 million (down 0.95% YoY) and the FY2025 annual result came in at $185.6 million, down 1.21% from the prior year.
- Non-Current Assets fell to $183.8 million in Q1 2026 per KMDA's latest filing, from $185.6 million in the prior quarter.
- Over the last five years, Non-Current Assets for KMDA reached as high as $354.7 billion in Q4 2023 and fell as low as $183.4 million in Q4 2022.
- A 5-year average of $40.9 billion and a median of $185.6 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets jumped 193350.02% — and 2024, when it tumbled 99.95%.
- Year by year, Non-Current Assets stood at $183.4 million in 2022, then soared by 193350.02% to $354.7 billion in 2023, then slumped by 99.95% to $187.9 million in 2024, then retreated by 1.21% to $185.6 million in 2025, then slipped by 1.0% to $183.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $183.8 million, $185.6 million, and $184.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 183.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 183.79 Mn |
| Dec 31, 2025 | 185.64 Mn |
| Sep 30, 2025 | 184.48 Mn |
| Jun 30, 2025 | 184.90 Mn |
| Mar 31, 2025 | 186.61 Mn |
| Dec 31, 2024 | 187.91 Mn |
| Sep 30, 2024 | 186.80 Mn |
| Jun 30, 2024 | 184.61 Mn |
| Mar 31, 2024 | 185.37 Mn |
| Dec 31, 2023 | 354.74 Bn |
| Sep 30, 2023 | 336.90 Bn |
| Jun 30, 2023 | 184.71 Mn |
| Mar 31, 2023 | 316.66 Mn |
| Dec 31, 2022 | 183.37 Mn |
| Sep 30, 2022 | 319.50 Mn |
| Jun 30, 2022 | 185.53 Mn |
| Mar 31, 2022 | 186.93 Mn |
| Dec 31, 2021 | 188.62 Mn |
| Sep 30, 2021 | 37.58 Mn |
| Jun 30, 2021 | 37.00 Mn |